Cadila Plant Gets FDA Warning Before it Begins Production

Ahmedabad-based Zydus Cadila, listed as Cadila Healthcare on Indian bourses, has received a warning letter from the US Food and Drug Administration (FDA) over violation of current good manufacturing practice (GMP) regulations for finished pharmaceuticals at its facility in Gujarat. The injectable drug plant of the group near Ahmedabad has not yet started production, but the FDA issued the warning letter on violations identified at the new plant following a pre-approval inspection. The regulator has given the company 15 days to take corrective measures and report back to it.